John Tumeh
Psychiatry · Atlanta, GANPI 1053540088
Payments from drug & device makers
Across 189 payments — averaging $45.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Acadia Pharmaceuticals Inc$1K
- Johnson & Johnson$889
- Neurocrine Biosciences, Inc.$725
- Teva Pharmaceuticals USA, Inc.$557
- AbbVie$456
- plus $3K from 28 others
What the payments were for
- Consulting fees$2,04023%
- Travel & lodging$80%
- Food & beverage$6,61176%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $1,840 |
| Acadia Pharmaceuticals Inc | 27 | $1,256 |
| Johnson & Johnson | 28 | $889 |
| Neurocrine Biosciences, Inc. | 16 | $725 |
| Teva Pharmaceuticals USA, Inc. | 17 | $557 |
| AbbVie | 27 | $456 |
| Janssen Scientific Affairs, LLC | 3 | $400 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $374 |
| Axsome Therapeutics, Inc. | 10 | $336 |
| Harmony Biosciences LLC | 7 | $216 |
| EMD Serono, Inc. | 2 | $186 |
| Jazz Pharmaceuticals Inc. | 3 | $182 |
| Supernus Pharmaceuticals, Inc. | 4 | $167 |
| Otsuka America Pharmaceutical, Inc. | 7 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $138 |
| Lilly USA, LLC | 2 | $131 |
| Corium, LLC | 4 | $108 |
| Forte Bio-pharma LLC | 1 | $88 |
| Lundbeck LLC | 2 | $74 |
| Tris Pharma Inc | 3 | $64 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Bausch Health US, LLC | 2 | $36 |
| Neos Therapeutics, LP | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Almatica Pharma LLC | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Biogen | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,690 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 17 | $18,935 |
| Lisdexamfetamine Dimesylate | 11 | $3,028 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,000 |
| Bupropion XlBupropion Hcl | 26 | $832 |
| Quetiapine Fumarate | 20 | $705 |
| Lurasidone Hcl | 13 | $542 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $537 |
| Lamotrigine | 22 | $414 |
| Fluoxetine Hcl | 16 | $398 |
| Trazodone Hcl | 23 | $329 |
| Escitalopram Oxalate | 15 | $105 |
| Mirtazapine | 15 | $99 |
| Methylphenidate Hcl | 13 | $89 |
| Zolpidem Tartrate | 13 | $74 |
| Clonazepam | 23 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $889 | $18,93517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.